Pinealon
Grade CRussian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.
Russian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.
Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.
Educational reference only — not medical advice.
Pinealon is administered intranasal or subcutaneous with an approximate systemic half-life of Short, hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.
Sterile technique is not optional. Use a fresh needle for every injection.
Download a printable version of this checklist to log baseline, weekly and post-cycle results.
Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.
Below are the primary references used to grade Pinealon. Follow the links for full-text where available and cross-check against the current literature.
1–10 mg, Daily, for 10–20 day cycles, 1–2× per year. Route: Intranasal or subcutaneous. Timing: Morning. Half-life: Short, hours.
Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.
Most users track a full 10–20 day cycles, 1–2× per year cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.
Research chemical; not approved for human therapeutic use.
Largely unknown long-term; Injection site or nasal irritation.
Commonly combined with: Epithalon, Magnesium glycinate. Introduce one compound at a time to preserve attribution.
Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for cognitive peptides (see the monitoring section on this page).
Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.
Further reading: Research library → · Protocols →
| Attribute | PinealonThis page | Dihexa | Retatrutide |
|---|---|---|---|
| Evidence | Grade C | Grade C | Grade A |
| Category | Cognitive | Cognitive | Metabolic |
| Best for | Cognitive resilience (research) | Cognitive plasticity (preclinical) | Triple GIP/GLP-1/glucagon agonist |
| Typical dose | 1–10 mg | 8–45 mg (anecdotal) | Titrated 2 mg → 4 mg → 8 mg → 12 mg |
| Frequency | Daily | Daily | Once weekly |
| Route | Intranasal or subcutaneous | Oral or transdermal (research) | Subcutaneous injection |
| Legal status | Research chemical; not approved for human therapeutic use. | Research chemical. Not approved for human use. Significant unknown oncologic risk. | Investigational; not yet FDA-approved. Currently available only via clinical trials. |
| Action | Current page | View → | View → |